EMA rejects Netherlands Cancer Institute's cheaper drug bid

The European Medicines Agency rejected the Netherlands Cancer Institute's application for a cheaper cancer drug, which was developed outside the pharmaceutical industry. The rejection, delivered in strong terms, marks a setback for efforts to reduce drug costs. The decision's rationale and implications for future non-industry drug development remain unclear.